These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 29453947)

  • 1. Evaluation of the effects of RP5063, a novel, multimodal, serotonin receptor modulator, as single-agent therapy and co-administrated with sildenafil, bosentan, and treprostinil in a monocrotaline-induced pulmonary arterial hypertension rat model.
    Bhat L; Hawkinson J; Cantillon M; Reddy DG; Bhat SR; Laurent CE; Bouchard A; Biernat M; Salvail D
    Eur J Pharmacol; 2018 May; 827():159-166. PubMed ID: 29453947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RP5063, a novel, multimodal, serotonin receptor modulator, prevents monocrotaline-induced pulmonary arterial hypertension in rats.
    Bhat L; Hawkinson J; Cantillon M; Reddy DG; Bhat SR; Laurent CE; Bouchard A; Biernat M; Salvail D
    Eur J Pharmacol; 2017 Sep; 810():92-99. PubMed ID: 28577964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RP5063, a novel, multimodal, serotonin receptor modulator, prevents Sugen 5416-hypoxia-induced pulmonary arterial hypertension in rats.
    Bhat L; Hawkinson J; Cantillon M; Reddy DG; Bhat SR; Laurent CE; Bouchard A; Biernat M; Salvail D
    Eur J Pharmacol; 2017 Sep; 810():83-91. PubMed ID: 28576407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil.
    Mouchaers KT; Schalij I; de Boer MA; Postmus PE; van Hinsbergh VW; van Nieuw Amerongen GP; Vonk Noordegraaf A; van der Laarse WJ
    Eur Respir J; 2010 Oct; 36(4):800-7. PubMed ID: 20351034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and histopathological relationship of sildenafil and bosentan treatments in rats with monocrotaline induced pulmonary hypertension.
    Karpuz D; Hallioglu O; Buyukakilli B; Gurgul S; Balli E; Ozeren M; Tasdelen B
    Bratisl Lek Listy; 2017; 118(9):544-551. PubMed ID: 29061062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Single Drug and Combined Short-term Administration of Sildenafil, Pimobendan, and Nicorandil on Right Ventricular Function in Rats With Monocrotaline-induced Pulmonary Hypertension.
    Nakata TM; Tanaka R; Yoshiyuki R; Fukayama T; Goya S; Fukushima R
    J Cardiovasc Pharmacol; 2015 Jun; 65(6):640-8. PubMed ID: 25806612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats.
    Porvasnik SL; Germain S; Embury J; Gannon KS; Jacques V; Murray J; Byrne BJ; Shacham S; Al-Mousily F
    J Pharmacol Exp Ther; 2010 Aug; 334(2):364-72. PubMed ID: 20430844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension.
    Mulvaney EP; Reid HM; Bialesova L; Bouchard A; Salvail D; Kinsella BT
    BMC Pulm Med; 2020 Apr; 20(1):85. PubMed ID: 32252727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic interaction between a PDE5 inhibitor (sildenafil) and a new adenosine A2A receptor agonist (LASSBio-1359) improves pulmonary hypertension in rats.
    Alencar AK; Carvalho FI; Silva AM; Martinez ST; Calasans-Maia JA; Fraga CM; Barreiro EJ; Zapata-Sudo G; Sudo RT
    PLoS One; 2018; 13(4):e0195047. PubMed ID: 29677206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventive effect of sildenafil on right ventricular function in rats with monocrotaline-induced pulmonary arterial hypertension.
    Yoshiyuki R; Tanaka R; Fukushima R; Machida N
    Exp Anim; 2016 Jul; 65(3):215-22. PubMed ID: 26876436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension.
    Tang Y; Tan S; Li M; Tang Y; Xu X; Zhang Q; Fu Q; Tang M; He J; Zhang Y; Zheng Z; Peng J; Zhu T; Xie W
    BMC Pulm Med; 2022 Apr; 22(1):142. PubMed ID: 35413880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary arterial hypertension induced by a novel method: Twice-intraperitoneal injection of monocrotaline.
    Zhuang W; Lian G; Huang B; Du A; Xiao G; Gong J; Xu C; Wang H; Xie L
    Exp Biol Med (Maywood); 2018 Aug; 243(12):995-1003. PubMed ID: 30099957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-122, a novel antagonist of serotonin receptor 5-HT2B, prevents monocrotaline-induced pulmonary arterial hypertension in rats.
    Zopf DA; das Neves LA; Nikula KJ; Huang J; Senese PB; Gralinski MR
    Eur J Pharmacol; 2011 Nov; 670(1):195-203. PubMed ID: 21914448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension.
    Mouchaers KT; Schalij I; Versteilen AM; Hadi AM; van Nieuw Amerongen GP; van Hinsbergh VW; Postmus PE; van der Laarse WJ; Vonk-Noordegraaf A
    Am J Physiol Heart Circ Physiol; 2009 Jul; 297(1):H200-7. PubMed ID: 19395550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats.
    Clozel M; Hess P; Rey M; Iglarz M; Binkert C; Qiu C
    Exp Biol Med (Maywood); 2006 Jun; 231(6):967-73. PubMed ID: 16741032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic therapeutic effects of 2-methoxyestradiol with either sildenafil or bosentan on amelioration of monocrotaline-induced pulmonary hypertension and vascular remodeling.
    Tofovic SP; Jones TJ; Bilan VP; Jackson EK; Petrusevska G
    J Cardiovasc Pharmacol; 2010 Nov; 56(5):475-83. PubMed ID: 20881615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treprostinil palmitil inhibits the hemodynamic and histopathological changes in the pulmonary vasculature and heart in an animal model of pulmonary arterial hypertension.
    Corboz MR; Plaunt AJ; Malinin V; Li Z; Gauani H; Chun D; Cipolla D; Perkins WR; Chapman RW
    Eur J Pharmacol; 2022 Feb; 916():174484. PubMed ID: 34508752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats.
    Leong ZP; Hikasa Y
    Vascul Pharmacol; 2018 Nov; 110():31-41. PubMed ID: 30071297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urantide alleviates monocrotaline induced pulmonary arterial hypertension in Wistar rats.
    Mei Y; Jin H; Tian W; Wang H; Wang H; Zhao Y; Zhang Z; Meng F
    Pulm Pharmacol Ther; 2011 Aug; 24(4):386-93. PubMed ID: 21396478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats.
    Hill NS; Warburton RR; Pietras L; Klinger JR
    J Appl Physiol (1985); 1997 Oct; 83(4):1209-15. PubMed ID: 9338430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.